Biological Evaluation of Medical Devices

Key guidance on how to use the ISO 10993 series of standards and successfully apply a risk management approach to the biological evaluation of medical devices.

18-19 May 2020

& 25-26 Nov 2020

GBP 1,499
EUR 2,099
USD 2,338

Book now

Course overview

New for 2019

The ISO 10993 series of standards covering biological evaluation of medical devices is well established and regulatory authorities worldwide expect compliance. In Europe compliance with the standards will be the easiest way to meet the relevant essential product safety requirements of the Medical Device Regulation. Understanding a risk management approach to biological evaluation is essential.

This seminar will provide key guidance on how to use the standards and successfully apply a risk management approach to the biological evaluation of medical devices. There will be plenty of time for interactive discussion with experts in this field.

Who should attend?

This seminar will be of importance to those in the medical device industry from the following departments:

  • Regulatory affairs
  • R&D
  • Product safety/toxicology
  • Analytical chemistry
  • Risk assessment and risk management
  • Materials research and evaluation
  • It will be of particular interest to Regulatory Authorities, Notified Bodies and CROs regulating or supporting the medical device industry

Programme day one

An introduction to medical devices

An introduction to biocompatibility

Biocompatibility vs biological safety

ISO 10993 history and development

ISO 10993 structure and content

ISO/TR 15499 and 10993/1 (2018)

Relationship between 10993 and 14971

Medical device categorisation for biological risk assessment

The move away from in vivo testing

Endpoints to be addressed in a biological risk assessment

Chemical characterisation vs chemical information

Physical characterisation

Guidance on technical aspects of specific biocompatibility tests

Programme day two

Extractables and leachables testing – when and why?

Risk assessment using E&L data

Medical Device Directive (MDD) safety requirements

Medical Device Regulation (MDR) safety requirements

Good Laboratory Practice (GLP)

The 510(K) process

FDA’s take on ISO 10993

Japanese requirements

Chinese requirements

MDR – gap analysis of existing data

Change management – impact on biological risk assessment

Questions and final discussion

Interactive workshops and discussion sessions will take place throughout the two days

Presenters

Philip Clay

Philip Clay is Director and principal toxicologist with Chorley Consulting. He is a UK and European registered toxicologist and specialises in product safety assessment with over 30 years’ experience in toxicology and safety assessment. He is a BSI committee member on CH/194 (Biological evaluation of medical devices) and Principal Expert for WG6 (Mutagenicity, carcinogenicity and reproductive toxicity).
Philip established his reputation as a genetic toxicologist working within the agrochemical, chemical and pharmaceutical industries. He has contributed to many expert panels, helping to shape the testing guidelines and strategies in place today. More recently, this experience and depth of understanding has been applied to designing safety assessment programmes for medical devices and consumer healthcare products for a wide range of clients. Philip is presently a member of a Consumer Healthcare Products Association (CHPA) expert group lobbying US FDA regarding the use of in vitro data in the assessment of the biocompatibility of medical devices.
He has extensive experience in the biological safety evaluation of a wide range of medical devices from Class 1 consumer healthcare devices through to Class 3 implantable devices. He is an experienced speaker at scientific conferences and has delivered training on biological safety evaluation around the world.

Janine Ingleby

Janine Ingleby is a Senior Safety Assessor with Chorley Consulting. She holds a MSc in Global aquatic biodiversity and a BSc in Molecular biology and biotechnology, both from the University of Hull. She has over 10 years of regulatory and product safety experience within FMCG and the Fragrance industry. She also holds a Prince2 practitioner qualification in project management. Janine has a great depth of knowledge in the regulation of cosmetics and fragrances as well as having toxicological data analysis skills for use in risk assessments of medicines, medical devices, cosmetics and general products.
She is an experienced presenter with particular strengths in the regulatory and quality management aspects of the biological evaluation of medical devices.

Book now

18-19 May 2020
18-19 May 2020 Cavendish Hotel, London GBP 1,499.00
EUR 2,099.00
USD 2,338.00
+ VAT @ 20.00%
Enrol now
25-26 Nov 2020
25-26 Nov 2020 Venue not yet confirmed GBP 1,499.00
EUR 2,099.00
USD 2,338.00
+ VAT @ 20.00%
Online registration unavailable: this date is nearing full capacity; please call us on 020 7749 4730 to register.

Previous customers include...

  • ABBOTT IRELAND
  • Allergan Medical
  • BAUSCH & LOMB INC
  • Biocompatibles UK Ltd
  • BioTop Medical
  • Cardinal Health
  • Cook Ireland Ltd
  • Covidien
  • DEPUY
  • Depuy CMW
  • Eurofins Biolab Srl
  • Fresenius HemoCare Netherlands BV
  • ITL LIMITED
  • LAB Research (Scantox)
  • Mentor Medical Systems B.V.
  • Merck Sharp & Dohme
  • Omron Healthcare Europe BV
  • Pall Europe Limited
  • Q-Med AB
  • QUINTILES CONSULTING - MTC
  • Renishaw plc
  • Russell Square Quality Associates Limited
  • Smith & Nephew Wound Management
  • Smiths Medical International Limited
  • Sphere Medical Ltd
  • SSL INTERNATIONAL
  • Synthes GmbH
  • Tissue Science Laboratories PLC
  • Wellspect Healthcare
  • William Cook Europe ApS